CKD is a systemic inflammatory disease with strong impact on whole body organs, pathophysiology of anemia in CKD patient now is referred to chronic inflammatory state and increased oxidative stress in such disease. G6PD enzyme is one of the antioxidant enzymes in cellular physiology. sixty four hemodialysis anemic patients were included in the study. They were dividedinto two groups of equal numbers (before correction of anemia by EPO & patients already on EPO). The two groups were compared according to G6PD assay, indirect bilirubin and corrected reticulocyte count. The mean (SD) erythrocyte G6PD activity for patients who not receive adequate EPO therapy was (4.41 ± 3.59) U/g Hb compared to Patients who had received adequate EPO therapy had a significantly higher average erythrocyte G6PD, the mean (SD) was (8.90 ± 3.60) U/g Hb (Pvalue <0.001). Also G6PD wasinversely proportional to duration of HD in patient receiving EPO (P value = 0.006). Indirect bilirubin & corrected reticulocyte count were significantly decreased after use of adequate EPO therapy (P value = 0.035) for indirect bilirubin while (P value <0.001) for corrected reticulocyte count. EPO has antioxidative effect through normalizing erythrocyte G6PD which seems to be acquired deficient in ESRD patient by the oxidative process in chronic disease.